



FOR IMMEDIATE RELEASE

PPD Recognized for Wellness Programs Focused on Employees' Health

WILMINGTON, N.C., (December 7, 2015) – Pharmaceutical Product Development, LLC ([PPD](#)) today announced it has been recognized as one of the best companies for promoting employee health and wellness in the North Carolina Research Triangle area.

PPD was ranked fourth on the list of the 25 Healthiest Employers of the Triangle, an award sponsored by the *Triangle Business Journal*. The honor recognizes PPD's commitment to [prioritizing wellness](#) and helping employees focus on their health.

“As a company dedicated to helping biopharmaceutical clients develop life-changing medical treatments, PPD believes strongly in supporting employees in their efforts to lead healthier lives,” said Ed Murray, executive vice president of human resources. “This award recognizes that support for PPD's wellness programs is an investment in the health of our employees and our company. Our philosophy is simple: Healthier, happier employees are more productive, engaged employees.”

PPD employees are encouraged to be wise health care consumers and to participate in the company's [wellness programs](#), pursue a healthy lifestyle, and integrate fitness and good nutrition into their daily lives. Sustained engagement in these programs provides the greatest potential for employees and their dependents to live healthy and productive lives, and supports PPD's objective of maintaining ongoing competitive and affordable health care benefit offerings.

Employees access online wellness tools and health education resources, as well as participate in worksite wellness programs that encourage employees to know their numbers – blood pressure, cholesterol and more – to be informed about lifestyle choices.

PPD supports employee involvement in walks, runs and races and sponsors the [PPD Beach2Battleship Triathlon](#), featuring PPD Heroes – athletes who champion clinical research by sharing their personal stories of overcoming illness with medical treatments developed in clinical trials.

In the healthiest employers honors program, winning companies completed an online assessment with Healthiest Employers Inc. This nonbiased measurement scored wellness programs in comparison to regional and national employers.

About PPD

PPD is a leading global [contract research organization](#) providing [drug discovery](#), development, lifecycle management and [laboratory](#) services. Our clients and partners include [pharmaceutical](#), [biotechnology](#), [medical device](#), academic and [government](#) organizations. With offices in 46 countries and more than 14,500 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to

help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppd.com.

PPD Contacts

Media:

Elizabeth Humphrey

+1 910 558 6096

elizabeth.humphrey@ppdi.com

Investors:

Nate Speicher

+1 910 558 6783

nate.speicher@ppdi.com

Except for historical information, all of the statements, expectations and assumptions, including statements, expectations and assumptions about PPD's wellness programs contained in this news release are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based and could cause actual results to differ materially from the forward-looking statements. Other important factors that could cause future results to differ materially include the following: risks associated with and dependence on strategic relationships; risks associated with acquisitions and investments; the ability to attract, integrate, retain and train key personnel; competition in the outsourcing industry; PPD's ability to win new business; overall global economic conditions; economic conditions, research and development spending, and outsourcing trends in the pharmaceutical, biotechnology and government-sponsored research sectors; loss, delay or modification of large contracts; higher-than-expected cancellation rates; the rate of conversion of backlog into revenue; consolidation in the pharmaceutical and biotechnology industries; rapid technological advances that make our services or capabilities less competitive; the ability to control SG&A spending; compliance with drug development regulations; changes in the regulation of the drug development process; and actual operating performance. PPD assumes no obligation and expressly disclaims any duty to update these forward-looking statements in the future, except as required by applicable law. These forward-looking statements should not be relied upon as representing PPD's estimates or views as of any date subsequent to the date hereof.

###